Bristol-Myers Squibb

Using Bristol-Myers’ popular leukemia drug to improve anti-PD-1 cancer immunotherapy
Using Bristol-Myers’ popular leukemia drug to improve anti-PD-1 cancer immunotherapy
Fierce Biotech
cancer
Cedars Sinai
Bristol-Myers Squibb
Sprycel
anti-PD-L1
Flag link:
Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
Yahoo/Reuters
Nektar
Bristol-Myers Squibb
bladder cancer
NKTR-214
Opdivo
Flag link:
Starboard gauges Bristol-Myers shareholder support for Celgene deal
Starboard gauges Bristol-Myers shareholder support for Celgene deal
Yahoo/Reuters
Bristol-Myers Squibb
Celgene
M&A
Starboard
shareholders
Flag link:
Exelixis Proves Being Second Can Work Out Well
Exelixis Proves Being Second Can Work Out Well
Motley Fool
Exelixis
Bristol-Myers Squibb
Cabometyx
kidney cancer
Flag link:
Bladder cancer readout sees Nektar shares hit
Bladder cancer readout sees Nektar shares hit
Fierce Biotech
Nektar Therapeutics
bladder cancer
NKTR-214
Opdivo
Bristol-Myers Squibb
Flag link:
Asco-GU – Bristol’s renal cancer lead looks to be short-lived
Asco-GU – Bristol’s renal cancer lead looks to be short-lived
EP Vantage
renal cell carcinoma
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
clinical trials
Sutent
Flag link:
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Endpoints
Regeneron
Merck
Bristol-Myers Squibb
PD-1/L1 therapy
Libtayo
Keytruda
Opdivo
non-small cell lung cancer
Flag link:
Bristol-Myers' rumored activists 'haven't made a decision' on the company yet: Starboard CEO
Bristol-Myers' rumored activists 'haven't made a decision' on the company yet: Starboard CEO
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Flag link:
Powerful Senate committee invites pharma executives to testify
Powerful Senate committee invites pharma executives to testify
Reuters
Senate
drug pricing
AbbVie
AstraZeneca
Bristol-Myers Squibb
JNJ
Merck
Pfizer
Sanofi
Flag link:
Starboard Value Is to Take Stake in Bristol-Myers Squibb
Starboard Value Is to Take Stake in Bristol-Myers Squibb
Bloomberg
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Flag link:
Bristol-Myers yanked its Celgene bid days before deadline—and got a better price
Bristol-Myers yanked its Celgene bid days before deadline—and got a better price
Fierce Pharma
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Report: five companies would take brunt of Trump Part B proposal
Report: five companies would take brunt of Trump Part B proposal
BioCentury
Donald Trump
Medicare Part B
Amgen
Regeneron
Bristol-Myers Squibb
Genentech
Roche
Flag link:
What’s BMS saying about its Celgene buy behind the scenes? This transcript tells all
What’s BMS saying about its Celgene buy behind the scenes? This transcript tells all
Fierce Pharma
M&A
Celgene
Bristol-Myers Squibb
Flag link:
Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene
Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene
Motley Fool
Bristol-Myers Squibb
earnings
M&A
Celgene
Flag link:
BMS talks up Celgene merger to divert Opdivo disappointment
BMS talks up Celgene merger to divert Opdivo disappointment
Fierce Pharma
Bristol-Myers Squibb
Celgene
Opdivo
Yervoy
Flag link:
Good latest quarter from BMS
Good latest quarter from BMS
GoinPharma
Bristol-Myers Squibb
earnings
Flag link:
In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo
In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo
Xconomy
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
FDA
Flag link:
A flashy 2019 start to pharma M&A, but will it last?
A flashy 2019 start to pharma M&A, but will it last?
Biopharma Dive
M&A
Celgene
Bristol-Myers Squibb
Eli Lilly
Loxo Oncology
Flag link:
Is the Smoldering NASH Market Ready to Burst Into Flames?
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Flag link:
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing
Stat
Celgene
drug pricing
M&A
Bristol-Myers Squibb
Flag link:

Pages